Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista de la Facultad de Medicina
versión impresa ISSN 0120-0011
Resumen
AROCA-MARTINEZ, Gustavo et al. Response to pharmacotherapy in patients with membranoproliferative glomerulonephritis in a hospital of Barranquilla, Colombia, between 2007 and 2014. rev.fac.med. [online]. 2018, vol.66, n.3, pp.301-305. ISSN 0120-0011. https://doi.org/10.15446/revfacmed.v66n3.63178.
Introduction:
Membranoproliferative glomerulonephritis (MPGN) is a pattern of mesangial hypercellular glomerular lesion with thinning of the glomerular basement membrane and endocapillary proliferation, mediated by immunoglobulin and the complement system of the mesangium and capillary endothelium.
Objective:
To assess the response to pharmacotherapy in patients diagnosed with MPGN in a hospital of Barranquilla between 2007 and 2014.
Materials and methods:
Retrospective cohort study in which 58 patients diagnosed with MPGN by renal biopsy were assessed and classified as responsive and non-responsive. A standard treatment assessment was performed according to the type of MPGN: mediated by the complement system, mediated by immunocomplexes, and negative immunofluorescence at 6 and 12 months of treatment.
Results:
The average age of the participants was 35±13 years. Of 58 patients, 52% were female, 63% developed chronic kidney disease (CKD) one year after the assessment, 25.8% achieved remission (22.4% complete and 3.4% partial) and 74.2% failed to enter remission.
Conclusion:
MPGN is one of the most important causes of CKD among the studied population. Response to immunosuppressant treatment showed no statistically significant benefits, regardless of the type of MPGN.
Palabras clave : Glomerulonephritis; Membranoproliferative Glomerulonephritis; Nephrotic Syndrome; Immunosuppression (MeSH).